Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Risedronic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS known ✓ | P14324 | 9/20 | 0.71 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.71 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.45 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Risedronic Acid SCHEMBL5175755 | 0.92 | FDPS (0.80) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL5176322 | 0.92 | FDPS (0.70) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL18377 | 0.86 | FDPS (0.80) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL29380338 | 0.86 | FDPS (0.80) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL29738088 | 0.85 | FDPS (0.78) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL4755300 | 0.85 | FDPS (0.78) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL5970387 | 0.85 | FDPS (0.78) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL4643040 | 0.85 | FDPS (0.83) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL536966 | 0.85 | FDPS (0.78) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL3953153 | 0.85 | FDPS (0.78) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1252170-B2 | SELECTIVE CRYSTALLIZATION OF 3-PYRIDYL-1-HYDROXYETHYLIDENE-1,1-BISPHOSPHONIC ACID SODIUM AS THE HEMIPENTAHYDRATE OR MONOHYDRATE | WARNER CHILCOTT CO LLC (PR) | 2013-11-06 | — | — | EP | claimed |
| EP-1981896-B1 | AN IMPROVED PROCESS FOR THE PREPARATION OF RISEDRONATE SODIUM HEMI-PENTAHYDRATE | AUROBINDO PHARMA LTD (IN) | 2013-03-13 | — | — | EP | claimed |
| US-7485726-B2 | Process for the preparation of risedronate sodium hemi-pentahydrate | AUROBINDO PHARMA LTD. (IN) | 2009-02-03 | — | — | US | claimed |
| US-20080300408-A1 | Process for Preparing a Pure Polymorphic Form of 3-Pyridyl-1-Hydroxyethylidine-1, 1-Bisphosphonic Acid Sodium Salt | JUBILANT ORGANOSYS LIMITED (IN) | 2008-12-04 | — | — | US | claimed |
| EP-1828214-A4 | PROCESS FOR PREPARING A PURE POLYMORPHIC FORM OF 3-PYRIDYL-1-HYDROXYETHYLIDINE-1,1-BISPHOSPHONIC ACID SODIUM SALT | JUBILANT ORGANOSYS LTD (IN) | 2008-08-13 | — | — | EP | claimed |
| WO-2008044245-A2 | A PROCESS FOR THE PREPARATION OF RISEDRONATE SODIUM HEMIPENTAHYDRATE | MATRIX LABORATORIES LTD (IN) | 2008-04-17 | — | — | WO | claimed |
| EP-1828214-A1 | PROCESS FOR PREPARING A PURE POLYMORPHIC FORM OF 3-PYRIDYL-1-HYDROXYETHYLIDINE-1,1-BISPHOSPHONIC ACID SODIUM SALT | Jubilant Organosys Limited (IN) | 2007-09-05 | — | — | EP | claimed |
| US-20070173484-A1 | Process for the preparation of risedronate sodium hemi-pentahydrate | AUROBINDO PHARMA LTD. (IN) | 2007-07-26 | — | — | US | claimed |
| WO-2006051553-A1 | PROCESS FOR PREPARING A PURE POLYMORPHIC FORM OF 3-PYRIDYL-1-HYDROXYETHYLIDINE-1,1-BISPHOSPHONIC ACID SODIUM SALT | JUBILANT ORGANOSYS LIMITED (IN) | 2006-05-18 | — | — | WO | claimed |
| EP-1252170-B1 | SELECTIVE CRYSTALLIZATION OF 3-PYRIDYL-1-HYDROXYETHYLIDENE-1,1-BISPHOSPHONIC ACID SODIUM AS THE HEMIPENTAHYDRATE OR MONOHYDRATE | PROCTER & GAMBLE (US) | 2004-08-18 | — | — | EP | claimed |
| US-6410520-B2 | HEATING IN AQUEOUS SOLUTION | THE PROCTER & GAMBLE COMPANY | 2002-06-25 | — | — | US | claimed |
| US-20020002282-A1 | Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate | ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED (IE) | 2002-01-03 | — | — | US | claimed |
| EP-1252170-B2 | SELECTIVE CRYSTALLIZATION OF 3-PYRIDYL-1-HYDROXYETHYLIDENE-1,1-BISPHOSPHONIC ACID SODIUM AS THE HEMIPENTAHYDRATE OR MONOHYDRATE | WARNER CHILCOTT CO LLC (PR) | 2013-11-06 | — | — | EP | disclosed |
| EP-1981896-B1 | AN IMPROVED PROCESS FOR THE PREPARATION OF RISEDRONATE SODIUM HEMI-PENTAHYDRATE | AUROBINDO PHARMA LTD (IN) | 2013-03-13 | — | — | EP | disclosed |
| US-20100317859-A1 | Process for the Preparation of Risedronate Sodium | ACTAVIS GROUP PTC EHF (IS) | 2010-12-16 | — | — | US | disclosed |
| US-7485726-B2 | Process for the preparation of risedronate sodium hemi-pentahydrate | AUROBINDO PHARMA LTD. (IN) | 2009-02-03 | — | — | US | disclosed |
| US-6410520-B2 | HEATING IN AQUEOUS SOLUTION | THE PROCTER & GAMBLE COMPANY | 2002-06-25 | — | — | US | disclosed |
| US-6410520-B2 | HEATING IN AQUEOUS SOLUTION | THE PROCTER & GAMBLE COMPANY | 2002-06-25 | — | — | US | disclosed |
| US-20020002282-A1 | Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate | ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED (IE) | 2002-01-03 | — | — | US | disclosed |
| US-20020002282-A1 | Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate | ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED (IE) | 2002-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173484-A1 | Process for the preparation of risedronate sodium hemi-pentahydrate | PTH1R, PHPT1, HPD | FDPS 61/4885BTN3A1 1592/4885PDE3A 1955/4885 |
| US-20020002282-A1 | Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate | PHPT1, PPA1, BPGM | FDPS 136/4885BTN3A1 792/4885PDE3A 2848/4885 |
| US-20100317859-A1 | Process for the Preparation of Risedronate Sodium | PPIP5K2, PDE8B, HMGCR | FDPS 23/4885BTN3A1 4441/4885PDE3A 379/4885 |
| US-20080300408-A1 | Process for Preparing a Pure Polymorphic Form of 3-Pyridyl-1-Hydroxyethylidine-1, 1-Bisphosphonic Acid Sodium Salt | BPGM, ENPP1, SLC20A1 | FDPS 458/4885BTN3A1 2406/4885PDE3A 2576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.